The biggest market for Acomplia in Europe is in Germany...

The drug company that makes the diet drug Acomplia is very keen to get governments to pay for the drug as part of state health care.  Sanofi Aventis argues that Acomplia is not just a weight loss drug but also a drug that can help with metabolic deficiencies experienced by some overweight and obese people. They are however having a difficult time in proving this and in both Germany and France, the health authorities will not reimburse the drug. In the United Kingdom the drug is undergoing scrutiny by the National Institute for Clinical Excellence which normally takes a couple of years before it issues a verdict on whether the state should pay for it.

Sanofi Aventis were so determined to get their way in Germany regarding the reimbursement of the cost of Acomplia that they took the committee who decided not to reimburse patients for the drug to court. Unfortunately for Sanofi Aventis they lost their case and people in Germany will therefore have to pay for the weight loss drug themselves.

The UK was the first European country to start selling the Acomplia weight loss drug and sales have been brisk, however the biggest market for Acomplia in Europe is in Germany where 50,000 individuals got prescriptions for Acomplia in the first five months of its sale there. Obviously the fact that the state does not reimburse these people is not of much concern to them. If you are serious about your weight loss the costs of Acomplia should not be a hindrance for the vast majority of people.

Acomplia is an appetite suppressant that works on the receptors in the human brain that control your desire to eat and has been approved for sale in Europe for over a year now. Like with all weight loss drugs you must also make a concerted effort to eat healthily and get exercise when you use them. Do not make the mistake that so many dieters make of expecting the weight loss drug to do all the work for you.